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Abstract
Chlorpromazine is a phenothiazine antipsychotic which is often used in hospice and palliative care to treat
hiccups, delirium, and nausea. With the discontinuation of the commercial oral solution concentrate, there is a
need to prepare this product by extemporaneous compounding. This study was initiated to identify an easy-
to-prepare formulation for the compounding pharmacist. A stability study was also conducted to select the
proper storage conditions and establish the beyond-use date. Chlorpromazine HCl powder and the Ora-
Sweet® syrup vehicle were used to prepare the 100 mg/mL solution. Once the feasibility was established, a
batch of the solution was prepared and packaged in amber plastic prescription bottles for a stability study.
These samples were stored at refrigeration (2–8°C) or room temperature (20–25°C) for up to 3 months. At
each monthly time point, the samples were evaluated by visual inspection, pH measurement, and high
performance liquid chromatography (HPLC). A separate forced stability study was conducted to confirm that
the HPLC method was stability indicating. A clear and colorless solution of 100 mg/mL chlorpromazine HCl
was obtained by dissolving the drug powder in Ora-Sweet® with moderate agitation. The stability study results
indicated that this solution product remained unchanged in visual appearance or pH at both refrigeration and
room temperature for up to 3 months. The HPLC results also confirmed that all stability samples retained
93.6–101.4% of initial drug concentration. Chlorpromazine HCl solution 100 mg/mL can be compounded
extemporaneously by dissolving chlorpromazine HCl drug powder in Ora-Sweet®. The resulting product is
stable for at least three months in amber plastic prescription bottles stored at either refrigeration or room
temperature.
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ABSTRACT 
Objective. Chlorpromazine is a phenothiazine antipsychotic which is often used in hospice 
and palliative care to treat hiccups, delirium, and nausea. With the discontinuation of the 
commercial oral solution concentrate, there is a need to prepare this product by 
extemporaneous compounding. This study was initiated to identify an easy-to-prepare 
formulation for the compounding pharmacist. A stability study was also conducted to select 
the proper storage conditions and establish the beyond-use date. 
Methods. The chlorpromazine HCl pure powder and the Ora-Sweet vehicle were used to 
prepare the 100 mg/mL solution. Once the feasibility was established, a batch of the 
solution was prepared and packaged in amber plastic prescription bottles for a stability 
study. These samples were stored at refrigeration (2-8C) or room temperature (20-25C) 
for up to three months. At each monthly time point, the samples were evaluated by visual 
inspection, pH measurement, and high performance liquid chromatography (HPLC). A 
separate forced stability study was conducted to confirm that the HPLC method was 
stability indicating.     
Results. A clear and colorless solution of 100 mg/mL chlorpromazine HCl was obtained 
by dissolving the drug powder in Ora-Sweet with moderate agitation. The stability study 
results indicated that this solution product remained unchanged in visual appearance or pH 
at both refrigeration and room temperature for up to three months. The HPLC results also 
confirmed that all stability samples retained 93.6-101.4% of initial drug concentration. 
Conclusion. Chlorpromazine HCl solution 100 mg/mL can be compounded 
extemporaneously by dissolving chlorpromazine HCl drug powder in Ora-Sweet®. The 
resulting product is stable for at least three months in amber plastic prescription bottles 
stored at either refrigeration or room temperature. 
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INTRODUCTION 
Chlorpromazine (Thorazine®) is a phenothiazine antipsychotic used in hospice and 
palliative care to treat hiccups, delirium, and nausea/vomiting at the end of life (EOL).1,2,3  
Currently chlorpromazine is commercially available as 10, 25, 50, 100, and 200 mg oral 
tablets and a 25 mg/mL solution for injection (all strengths expressed as the HCl salt form 
and thereafter).4 The concentrated oral solutions, also known as “intensol” formulations, 
are often preferred over tablets and injectables for symptom management in hospice 
outpatient, because the intensols can be easily given sublingually or buccally in patients 
with dysphagia from advanced disease.5 Family members may be uncomfortable giving an 
injectable medication in a home setting or have difficulty crushing tablets and mixing them 
in food prior to administration, so the intensols provide a valuable alternative product 
formulation. Chlorpromazine was previously available commercially as a 100 mg/mL oral 
solution concentrate.4 Unfortunately this product was discontinued by the manufacturer, 
creating a need for an extemporaneously compounded product. It is important to point out 
that the discontinuation was not due to any safety or efficacy reasons of the drug product.4 
This study was initiated to develop a formulation and procedure suitable for the 
compounding pharmacist. A long-term stability study was also conducted to select the 
storage conditions and establish the beyond-use date.   
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METHODS 
Sample Preparation 
 The calculated amount of chlorpromazine HCl powder (MP Biomedical LLC, 
Solon, OH; lot M2896) was accurately weighed and transferred into a pre-calibrated amber 
plastic prescription bottle or a glass volumetric flask. About 75% batch size of Ora-Sweet® 
syrup (Paddock Laboratories, Minneapolis, MN; NDC 0574-0304-16, lot 1356809) was 
added to the container followed by moderate intermittent agitation. A clear solution was 
typically obtained within 30 minutes. The remaining Ora-Sweet® was added to the mark, 
and the solution was mixed thoroughly. The density of this solution was determined to be 
1.30 g/mL (for the purpose of sample volume calculations as discussed below). A 
preliminary taste assessment was performed by three volunteers with a dose of 0.30 mL 
taken sublingually. 
Stability Study 
 Based on the procedure described above, a 250 mL batch of the chlorpromazine 
HCl solution in Ora-Sweet® was prepared in a volumetric flask for best accuracy. The 
solution was aliquoted into six amber plastic prescription bottles, 35 mL each. Three bottles 
were stored at refrigeration (2-8°C) and three at room temperature conditions (20-25°C). 
 Stability evaluation was performed immediately after preparation and after 1, 2, 
and 3 months of storage. At every time point, the three bottles from each temperature 
condition were pulled for analysis and returned to storage after sampling. About 0.5 mL 
from each bottle was taken for pH measurement (SevenEasy pH meter, Mettler-Toledo Inc., 
Columbus, OH), and about 1 mL for visual inspection followed by HPLC analysis. Due to 
the viscous nature of the solution, it was not possible to pipet the 1 mL samples accurately 
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based on volume. Instead, the aliquot from each sample was directly weighed in a tared 
10 mL volumetric flask. The target weight was calculated based on the density reported 
above. This sample was visually inspected against a light background for clarity, color, 
precipitation, and microbial growth. The sample was then serially diluted with HPLC 
mobile phase for HPLC analysis (see below). 
High-performance Liquid Chromatography (HPLC) 
 The HPLC analysis was performed using a Shimadzu model LC-2010A instrument 
(Shimadzu Scientific Instruments, Marlborough, MA). The chromatographic parameters 
were adapted from a stability indicating assay previously published by Kollmorgen et al.6 
A Symmetry C18 column (3.5 µ, 4.6150 mm, Waters, Milford, MA) was used and 
maintained at 40°C throughout analysis. The mobile phase consisted of water:methanol 
(36:64 v/v) with 0.1% trifluoroacetic acid; the flow rate was 0.5 mL/min. Each injection 
volume was 10 µL, and the UV detection was set at 254 nm. Under these conditions, the 
retention time of chlorpromazine was approximately 8.3 minutes. All samples for HPLC 
analysis were prepared by diluting the samples to a nominal concentration of 0.05 mg/mL 
using the mobile phase.  
 Standards of chlorpromazine HCl solutions were prepared at each time point for 
calibration purpose. Solutions of 0.03, 0.04, 0.05, 0.06, and 0.07 mg/mL were prepared by 
dissolving the calculated amount of chlorpromazine HCl powder in the mobile phase. A 
calibration curve was constructed at each time point by linear regression of the peak area 
of chlorpromazine against chlorpromazine concentration. The curve was found to be linear 
over the concentration range of the standards with a typical r2 = 0.999.  
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Forced Degradation Study 
 A short-term forced degradation study of chlorpromazine was conducted under 
extreme pH, sunlight, ultraviolet (UV) light and oxidative stress conditions. This study was 
intended to verify the ability of the HPLC assay to separate the potential degradation 
products from the parent drug. Three samples of 0.05 mg/mL chlorpromazine HCl solution 
were prepared in the mobile phase with 0.5 N HCl, 0.5 N NaOH, and 3% H2O2. These 
samples were incubated at 60°C for up to 3 days. Three additional samples of 0.05 mg/mL 
chlorpromazine HCl solution prepared in HPLC mobile phase were exposed to sunlight 
(on a windowsill) and UV light at 254 & 365 nm for 3 days. The UV light was generated 
by a standard laboratory hand-held UV lamp (Model ENF-240C, Spectronics Corporation, 
Westbury, NY). 
 Significant degradation was observed in all conditions except 0.5 N NaOH, and the 
degradation products were well separated from the parent molecule by the HPLC method 
with no interfering peaks observed. Therefore, the HPLC method was considered as 
stability-indicating and suitable for the stability evaluation of chlorpromazine HCl oral 
solution. 
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RESULTS AND DISCUSSION 
 The USP grade of chlorpromazine HCl pure powder is available commercially via 
multiple vendors, such as Sigma-Aldrich and Spectrum Chemical. This provides an ideal 
drug source to prepare a concentrated solution. The commercial chlorpromazine HCl 
tablets were also considered as the drug source, but they were not selected due to the 
presence of insoluble excipients. These insoluble excipients are undesirable for the 
buccal/sublingual delivery route and may negatively impact the drug absorption process. 
Ora-Sweet is a commonly used syrup vehicle, which provides flavoring and sweetness 
for taste-masking. Ora-Sweet also contains effective preservatives to prevent microbial 
growth over long-term storage.  
 The chlorpromazine HCl powder was found to dissolve in Ora-Sweet to yield a 
clear and colorless solution of 100 mg/mL. A recommended compounding procedure for 
the pharmacists is provided in Appendix A. The batch size of 20 mL is selected based on 
the typical dose range and 2-week refill schedule used for hospice outpatients. The amber 
prescription bottles are required for long-term storage, because chlorpromazine is light 
sensitive based on previous reports and current findings from the forced stability study.7,8 
Triplicate samples were prepared following the recommended compounding procedure. 
The initial potency (drug concentration) was determined by HPLC to be 99.1  5.5 mg/mL. 
This is within the 10% of the nominal potency and is considered satisfactory.  
 The palatability of the compounded chlorpromazine HCl solution was assessed by 
three volunteers. Despite the taste masking effect of the Ora-Sweet vehicle, the solution 
tasted bitter. Additionally, the solution exhibited an anesthetic numbing effect in the mouth 
for about 2-3 hours after administration.  However, the bitter taste and numbing effect are 
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not expected to be a main concern for hospice patients given that intensol preparations are 
typically reserved for symptom management in patients with dysphagia and decreased level 
of consciousness related to advanced disease. 
 For the long-term stability study, the initial sample pH and potency values are 
reported in Tables 1 & 2. Over the three months of storage at refrigeration (2-8C) or room 
temperature (20-25C), all samples remained clear, colorless, and free of visible 
precipitation or microbial growth. No significant change in pH was observed for any 
samples (Table 1). The stability-indicating HPLC analysis also confirmed that all samples 
retained 93.6-101.4% initial drug concentration (Table 2) with no new peaks observed. 
Overall, the chlorpromazine HCl solution 100 mg/mL was found to be stable in amber 
plastic prescription bottles at both refrigeration and room temperature for up to three 
months. 
 
CONCLUSION  
A concentrated oral solution of chlorpromazine HCl was formulated to treat hiccups, 
delirium, and nausea in hospice and palliative care patients. The 100 mg/mL solution can 
be conveniently prepared by dissolving USP grade of chlorpromazine HCl drug powder in 
Ora-Sweet®. The resulting solution product is stable for at least three months in amber 
plastic prescription bottles stored at either refrigeration or room temperature. 
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APPENDIX A. Compounding Procedure for Chlorpromazine HCl Oral Solution 
100 mg/mL (20 mL batch) 
1. Calibrate a suitable amber plastic prescription bottle for 20 mL 
2. Weigh out 2.0 g of chlorpromazine HCl powder accurately  
3. Transfer the drug powder into the pre-calibrated amber plastic bottle 
4. Add ~15 mL of Ora-Sweet® to the bottle 
5. Apply moderate intermittent agitation until the drug powder dissolves (~ 30 minutes) 
6. QS with additional Ora-Sweet® to the 20 mL mark and mix well 
7. Label the bottle with a 90 day expiration date and store at room temperature 
NOTE: It is important to use amber bottles or other light resistant containers for long-term 
storage, because chlorpromazine is light sensitive. 
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Table 1. pH Results of Chlorpromazine HCl Solution Stability Samples 
 
Storage 
Temperature 
(°C)  
pH a 
Time 0 1-month 2-month 3-month 
2 – 8 
3.57  0.43 
3.50  0.02 3.51  0.01 3.71  0.05 
20 – 25 3.52  0.01 3.48  0.01 3.77  0.02 
 
a Mean ± SD of three replicate samples (n = 3). 
 
 
 
 
Table 2. HPLC Results of Chlorpromazine HCl Solution Stability Samples 
 
Storage 
Temperature  
(°C) 
Initial Drug 
Concentrationa 
(mg/mL) 
% initial concentration remaininga 
1-month 2-month 3-month 
2 – 8  
104.9  2.0 
97.1  1.8 101.4  1.0 94.2  0.9 
20 – 25 97.2  0.1 101.4  1.2 93.6  1.6 
 
a Mean ± SD of three replicate samples (n = 3). 
 
